Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Gene expression analysis of effects of Met on BMDMs co-cultured with COM-TECs.

ABSTRACT: Gene expression analysis of effects of Met on BMDMs co-cultured with COM-TECs.

PROVIDER: PRJNA792154 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR17329359_1.fastq.gz	Fastqsanger.gz
	SRR17329359_2.fastq.gz	Fastqsanger.gz
	SRR17329360_1.fastq.gz	Fastqsanger.gz
	SRR17329360_2.fastq.gz	Fastqsanger.gz
	SRR17329361_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 36

Similar Datasets

Gene expression analysis of effects of Met on BMDMs co-cultured with COM-TECs.

Project description:Microarray analysis was used to assess the expression levels of mRNAs in bone marrow-derived macrophages (BMDMs) pretreated with metformin (Met) or PBS and co-cultured with renal tubular epithelial cells (TECs) or COM-TECs (NC vs. COM, COM vs. COM + Met).BMDMs and TECs were isolated from wild-type (WT) C57BL/6J mice. To developed a BMDM-COM-stimulated TECs co-culture system, BMDMs were plated in the upper chamber of 6-well Transwell plates with a pore size of 0.4 μm (Corning, USA), while TECs were plated in the lower chamber. In the COM and COM + Met groups, TECs were treated with COM (100 μg/mL) for 24 h and BMDMs were treated with Met (5.0mM) for 24 h.

2021-12-29 | GSE192593 | GEO

Estudo de avaliação do efeito do tratamento profiláctico do rash com o fármaco monociclina em doentes com diagnóstico de cancro colo-rectal metastizado que estejam a receber tratamento com cetuximab.

Project description:Primary objectives: Avaliar a eficácia da abordagem profilática com minociclina no desenvolvimento de toxicidade dermatológica secundária ao cetuximab Primary endpoints: Percentagem de doentes que desenvolvem rash associado ao tratamento com cetuximab para o cancro colo-rectal, no grupo experimental comparativamente com o grupo controlo

| 2529318 | ecrin-mdr-crc

com.1 gene

Project description:barley com.1 gene sequence

| PRJEB36813 | ENA

Moorella thermoacetica strain:COM

Project description:Moorella thermoacetica COM Genome sequencing and assembly

| PRJNA996483 | ENA

Terrisporobacter vanillatitrophus strain:COM

Project description:Terrisporobacter vanillatitrophus COM Genome sequencing and assembly

| PRJNA989104 | ENA

Array comparative genomic hybridization of Canine Oral Melanoma (COM) archival samples.

Project description:The aim of this work was to identify the Copy Number Aberrations (CNAs) by high-resolution array Comparative Genomic Hybridization (aCGH) on 19 formalin-fixed, paraffin-embedded (FFPE) samples of treatment-naïve COM.

2020-01-13 | GSE131923 | GEO

Terrisporobacter vanillatitrophus strain:COM

Project description:Terrisporobacter vanillatitrophus strain:COM Genome sequencing and assembly

| PRJNA1068316 | ENA

MET regulates expression of co-stimulatory and co-inhibitory molecules in tumor cells and contributes to suppression of immune cell function

Project description:MET-altered human cancer cell lines including Hs746T (MET-mutated/amplified), H596 (MET-mutated) and H1993 (MET-amplified) cells were used. In microarray analysis, MET suppression using MET inhibitor or siRNAs up-regulated variable co-stimulatory molecules, including 4-1BBL, OX40L and CD70, and down-regulated variable co-inhibitory molecules. Among co-inhibitory molecules, PD-L1 was one of the most markedly down-regulated genes by MET suppression, which was validated at the mRNA and total/surface protein levels in Hs746T and H1993 cells. Consistently, MET activation by HGF treatment increased PD-L1 expression in H596 cells. Co-culture of human peripheral blood mononuclear cells (PBMC) with Hs746T cells suppressed IFNg production from PBMC, which was restored by an MET inhibitor or PD-L1 blockade. A significant positive correlation between MET and PD-L1 expression was observed in The Cancer Genome Atlas (TCGA) analysis for variable cancer types and immunohistochemistry for lung cancer. MET overexpression in PD-L1-high tumor exhibited decreased expressions of T-cell effector molecules in TCGA analysis for lung cancer. In summary, MET overexpression/activation is related to immunosuppressive phenotype and is involved in immune escape of tumor by PD-L1 up-regulation. MET-targeted therapy combined with immunotherapy could be a potential therapeutic strategy in MET-dependent cancer.

2019-08-20 | GSE135976 | GEO

Co-dependency for MET and FGFR1 in basal triple negative breast cancers

Project description:Triple-negative breast cancer (TNBC) is a heterogeneous disease that lacks both effective patient stratification strategies and therapeutic targets. In the present study, we assay tumour-initiating cells (TICs) properties, using established Met-dependent transgenic mouse models of TNBC, breast cancer cell lines and, patient-derived xenografts, to directly investigate the role of Met in tumour initiation and identify FGFR1 signaling as a key convergent pathway with Met for the maintenance of TICs. To understand the events that occur in TICs upon inhibition of Met and FGFR1, we performed gene expression profiling by RNA-Sequencing of RNA prepared from tumoursphere from 3 independent MMTV-Metmt;Trp53fl/+;Cre derived spindloid tumour cell lines (A1005, A1129, A1471) following treatment with Met or FGFR inhibitor alone (Crizotinib or PD173074, respectively), or in combination for 24h.

2020-11-28 | GSE162272 | GEO

Expression data from WT and Klf3 KO BMDMs treated with LPS

Project description:Gene expression in bone marrow-derived macrophages (BMDMs) from WT and mice lacking the transcriptional repressor Kruppel-like factor 3 (KLF3). We cultured BMDMs from bone marrow for 7-10 days then treated cells with 100 ng/mL lipopolysaccharide (LPS) or vehicle (PBS) for 0 h or 8 h, followed by RNA extraction. We aimed to investigate deregulated genes and pathways in macrophages lacking KLF3, during the inflammatory response to endotoxin (LPS).

2020-03-24 | GSE121646 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data